| |
|
|
| |
Raymond F. Vennare is President, CEO and Co-Founder
of ThermalTherapeutic Systems. An accomplished senior executive
and serial entrepreneur with more than fifteen years of hands-on
experience building and growing information technology, informatics
and biotechnology companies across diverse markets, Raymond is
the former Chief Executive Officer of ImmunoSite, Inc., Senior
Vice President and Chief Information Officer of TissueInformatics,
Inc. and President of VS/Interactive, LLC. Collectively these companies
have raised in excess of $25 million from private, public, corporate
and professional investment sources. A frequent speaker on issues
related to leadership, business ethics, strategic thinking and
entrepreneurship, Raymond's expertise includes executive management,
corporate governance and the commercialization of emerging and
innovative new technologies.
|
|
Raymond F.Vennare
Co-Founder and
Chief Executive
Officer
|
|
|
|
|
| |
Joseph T. Donnelly,
a financial executive with 32 years of professional experience
in the healthcare industry, Joe began his career with Price Waterhouse.
He later joined Allegheny Health, Education & Research as
the Vice President and Corporate Controller and Chief Financial
Officer of Allegheny Singer Research Institute. Joe co-founded
Metamorphic Surgical Devices before the technology was acquired
by the Guidant Corporation. Most recently Joe served as Chief
Financial Officer of RedPath Integrated Pathology and Chief Financial
Officer for Vytrace Corporation. Joe serves on the Boards of
NSABP Foundation, a national research cooperative group that
conducts clinical trials for breast and colon cancer therapies,
and Axios Foundation, an international non-profit organization
focused on improving the healthcare delivery systems in developing
countries, particularly in Africa. |
|
Joseph T. Donnelly, CPA
Acting Chief Financial Officer
|
|
|
|
|
| |
J. Michael Fausset BS, CP is
Chief Technology Officer and Co-Founder of ThermalTherapeutic Systems
and former Vice-President of ViaCirq Incorporated. Mike is an experienced
perfusionist who has implemented and monitored clinical trials,
secured FDA clearance and enabled the marketing of medical devices.
Mike is a frequent speaker on the subject of hyperthermic treatments,
served as a reviewer for European Notified Body (CE mark) relative
to hyperthermic medical devices and holds several patents on hyperthermic
devices. In addition to training surgical oncologists specific
to hyperthermic procedures, Mike has been responsible for implementing
and monitoring clinical trials and securing regulatory approval
for medical devices. His successful submission and subsequent FDA
approval for a novel hyperthermic apparatus resulted in the marketing
of that device in Europe and the United States
|
|
J. Michael Fausset, BS, CP
Co-Founder and
Chief Technology Officer
|
|
|
|
|
| |
|
|
| |
Peter M. DeComo is Chairman
and CEO of Alung Technologies, Inc., a company which is currently
developing a revolutionary Artificial Lung technology for the
treatment of respiratory failure. Pete is the former Founder,
Chairman and CEO of Renal Solutions, Inc. where he raised $40
million in private equity financing and $25 million in debt financing
to fund the development of Renal's innovative Allient®, sorbent-based hemodialysis system. Renal
Solutions was acquired by Fresenius Medical Care Holdings for $200
million in November, 2007. Pete also sits on the Board of ClearCount
Medical Solutions, the developer of the SmartSponge System™ which
utilizes RFID chip technology for the counting and tracking of
sponges during surgical procedures in the operating room. In addition,
he is a Director on the Boards of the Pittsburgh Life Science Greenhouse
and the Pittsburgh Technology Council.
|
|
Peter M. DeComo
Co-Founder and
Chairman of the Board
|
|
|
|
|
| |
Raymond F. Vennare is
President, CEO and Co-Founder of ThermalTherapeutic Systems. An
accomplished senior executive and serial entrepreneur with more
than fifteen years of hands-on experience building and growing
information technology, informatics and biotechnology companies
across diverse markets, Raymond is the former Chief Executive Officer
of ImmunoSite, Inc., Senior Vice President and Chief Information
Officer of TissueInformatics, Inc. and President of VS/Interactive,
LLC. Collectively these companies have raised in excess of $25
million from private, public, corporate and professional investment
sources. A frequent speaker on issues related to leadership, business
ethics, strategic thinking and entrepreneurship, Raymond's expertise
includes executive management, corporate governance and the commercialization
of emerging and innovative new technologies. |
|
Raymond F.Vennare
Co-Founder and
Board Director
|
|
|
|
|
| |
Mary Del Brady is a serial
entrepreneur with more than thirty years of experience in building
companies in the services and biotechnology industries for which
she has raised more than $25 million in seed and venture capital. Mary
Del was founding CEO of RedPath Integrated Pathology, Inc. which
recently sold to ExonHit Therapeutics, S.A., a leading French diagnostics
and therapeutics biotech company, and Co-Founder and President
of TissueInformatics.Inc, later acquired by Clinical Data Inc.
Currently, she serves as Chairman of the Board and Acting CEO of
Cvergenx, Inc., a diagnostics services company that is developing
a genomics-based test to predict a patient’s sensitivity
to radiation therapy. She also serves on the Board of Intelomed,
Inc., a medical device company with a non-invasive platform technology
that measures the body’s physiological responses to stress
in real time for improved cardiovascular and fluid management.
|
|
Mary Del Brady
Co-Founder and
Board Director
|
|
|
|
|
| |
Mike Gausling, is the Managing
Director of Originate Venture Partners, a venture capital investment
firm targeting early stage companies in Pennsylvania and surrounding
regions with investments ranging from $1 million to $4 million.
Mike is the Co-founder and former CEO of OraSure Technologies
where he helped to build the company from a start-up to more
than $50 million in annual sales with a market cap of more than
$500 million over seventeen years. In that time, Mike has raised
more than $75 million from angel investors, venture capitalists,
public offerings, and commercial banks. Mike has held financial
management positions at Proctor & Gamble
and served as a Board member and Audit Chair at KNBT Bancorp.
Mike currently serves on the Life Science Advisory Board for Safeguard
Scientifics, Inc. and is Treasurer of LVIP, a non-profit land development
company in Bethlehem, PA.
|
|
Mike Gausling
Board Director
|
|
|
|
|
| |
Alan D. Hirschman, PhD,
is the former Director of Technology, Corporate Development and
Innovations at MEDRAD, Inc., where he contributed to that company’s
product portfolios, patent strategy and IP portfolio. With more
than 40 US patents issued, he is an inventor of several core MEDRAD
technologies. Alan’s breadth and depth of experience
in corporate strategic planning, technology commercialization,
innovation management, portfolio planning and acquisition of medical
diagnostic and therapeutic interventional products worldwide were
key to his success in a career spanning more than thirty years.
Alan was elected Fellow of American Institute for Medical and Biological
Engineering and Radiological Society of North America, serves as
Chairman, Industry Visiting Committee, University of Pittsburgh
Department of Biomedical Engineering and is a member of IEEE, Society
of Nuclear Medicine. |
|
Alan D. Hirschman, PhD
Board Director
|
|
|
|
|
| |
Larry Miller, Executive in Residence with Innovation
Works, collaborates with management teams of early stage life science
or medical device start-up technology companies. Larry has broad
experience in medical device and capital equipment marketing, sales
service and equipment finance. Prior to joining Innovation Works,
Larry was President and CEO of Biomec, a technology accelerator
and investment company which raised over $20M in SBIR grants. At
Picker International and Philips Medical systems, Larry was president
of the Healthcare Products group, a $ 600 million distributor of
radiology supplies, where he managed the Asia/ Pacific region for
sales and service of the diagnostic imaging product portfolio,
and was President of the Picker Financial Group. Other assignments
include marketing and sales of CT and MRI products for Picker and
General Electric Medical systems.
|
|
Larry Miller
Board Observer
|
|
|
|
|
| |
David S. Smith,
a corporate lawyer focusing on intellectual property transactions,
venture financings and regulatory matters for life sciences companies
and investors, is of counsel with Pepper Hamilton LLP. David
is founder and principal of Teregenics, LLC, providing strategic
product development analysis to investors, research centers and
companies developing human tissue engineering and regeneration
technologies. He was senior
vice president and general counsel of TissueInformatics.Inc and,
before that, of counsel at Reed Smith, LLP where he led the development
of that firm’s biotechnology practice. David is an
adjunct professor in Carnegie Mellon University’s Department
of Engineering and Public Policy, former member of the Scientific
Advisory Board of Clinical Cell Culture, trustee of AMD3 Research
Foundation, and serves on the executive committee of Tissue Engineering
and Regenerative Medicine International Society. |
|
David S. Smith
Board Secretary
|
|
|
|
|
| |
|
|
| |
James J. Rogers is Managing Director of Coastal
Consulting Group and has worked in engineering, service, regulatory
affairs, and quality assurance capacities for large, small and
early stage diagnostic imaging medical device manufacturers since
1987. Jim has been a member of numerous domestic and international
product development teams and has expertise in the regulation of
a broad variety of medical devices, including radiation therapy,
bone densitometry (DEXA) scanners, interventional radiology, medical
image management systems, wound irrigation and OTC/consumer products.
Jim has successfully submitted and defended more than seventy 510(k)
applications to the FDA, developed study protocols for clinical
trials, obtained IRB approvals, evaluated ninety-five investigational
devices and holds a patent for MRI cardiac gating technology.
|
|
James J. Rogers
Regulatory Affairs and
Quality Assurance
|
| |
|
|
|
|
